Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent Number 12128039 - October 29, 2024
The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically…
Anti-ROR antibody constructs
Patent Number 12084496 - September 10, 2024
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
Liquid dosage forms to treat cancer
Patent Number 12016854 - June 25, 2024
This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors,…
Crystalline forms and salt forms of a kinase inhibitor
Patent Number 12017995 - June 25, 2024
The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to…
Method of treating cancer
Patent Number 11969419 - April 30, 2024
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases,…
MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Application Number 20240010751 - January 11, 2024
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…
MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Application Number 20240010751 - January 11, 2024
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…
CD47 BINDING AGENTS AND USES THEREOF
Application Number 20230357391 - November 9, 2023
The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and…
PD-L1 BINDING AGENTS AND USES THEREOF
Application Number 20230303699 - September 28, 2023
The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and…
ANTI-ROR ANTIBODY CONSTRUCTS
Application Number 20210155692 - May 27, 2021
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
Exelixis, Inc. v. Sun Pharmaceutical Industries Ltd. et al
Delaware District Court - October 30, 2024
Spector v. EXELIXIS, INC.
California Northern District Court - September 12, 2024
Exelixis, Inc. v. Cipla Ltd. et al
Delaware District Court - May 9, 2024
Smith v. EXELIXIS, INC.
California Northern District Court - May 1, 2024
YOUNG v. EXELIXIS, INC.
Pennsylvania Eastern District Court - December 20, 2023
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware District Court - October 15, 2024
TRIAL OPINION: For the foregoing reasons, I find the asserted claim of the '349 patent not infringed and not invalid. I find the…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware District Court - April 20, 2022
MEMORANDUM ORDER: I DENY the Daubert motion. (D.I. 257). The issue could be appropriate for a motion in limine, although based on what is…
Exelixis, Inc. v. Honorable David J. Kappos
Virginia Eastern District Court - January 28, 2013
MEMORANDUM OPINION in re 16 Motion for Summary Judgment and 13 Motion for Summary Judgment. Signed by District Judge Leonie M. Brinkema…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware Delaware District Court - October 15, 2024
TRIAL OPINION: For the foregoing reasons, I find the asserted claim of the '349 patent not infringed and not invalid. I find the asserted…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware Delaware District Court - January 19, 2023
TRIAL OPINION: MSN failed to prove by clear and convincing evidence that claims 5 of the '473 patent is invalid as obvious. Exelixis…
Artt v. Exelixis US LLC
Texas Texas Northern District Court - March 28, 2022
MEMORANDUM OPINION AND ORDER granting 19 Motion for Summary Judgment. (Ordered by Senior Judge A. Joe Fish on 3/28/2022) (jmg)
